BridgeBio Pharma, Inc. (BBIO) vs Penumbra, Inc. (PEN)
A side-by-side comparison of BridgeBio Pharma, Inc. and Penumbra, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBIO
BridgeBio Pharma, Inc.
$66.14HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
PEN
Penumbra, Inc.
$317.11HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — BBIO vs PEN
growth of $100 · dividends reinvested · last 7yBBIO +140.1% (+13.3%/yr)PEN +95.8% (+10.1%/yr)BBIO compounded faster over this window
BBIO PEN
BBIO vs PEN: by the numbers
- •BBIO is the larger company ($12.95B vs $12.49B market cap).
- •PEN is profitable (10.67% net margin) while BBIO runs a net loss (-97.64%).
- •BBIO grew revenue faster over the past five years (62.61% vs 17.52% CAGR).
Metrics side by side
Valuation
| Metric | BBIO | PEN |
|---|---|---|
| P/E ratio | N/A | 77.91 |
| Forward P/E | N/A | 67.36 |
| P/S ratio | 18.17 | 8.30 |
| P/B ratio | N/A | 8.16 |
| EV / EBITDA | N/A | 61.12 |
| FCF yield | N/A | 1.73% |
Profitability
| Metric | BBIO | PEN |
|---|---|---|
| Gross margin | 93.35% | 67.84% |
| Operating margin | -113.35% | 12.45% |
| Net margin | -97.64% | 10.67% |
| ROE | N/A | 10.49% |
| ROIC | -62.14% | 8.48% |
Growth (annualized)
| Metric | BBIO | PEN |
|---|---|---|
| Revenue CAGR (5Y) | 62.61% | 17.52% |
| Total return CAGR (5Y) | 7.38% | 4.16% |
Frequently asked
- Which has grown faster, BBIO or PEN?
- Over the past five years, BBIO grew revenue faster — BBIO at a 62.61% CAGR versus PEN at 17.52%.
- Is BBIO or PEN more profitable?
- PEN runs the higher net margin — BBIO at -97.64% versus PEN at 10.67%.
- How have BBIO and PEN total returns compared?
- Over the past 5 years, BBIO delivered 7.38% and PEN delivered 4.16% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Penumbra P/E ratioBridgeBio Pharma ROEPenumbra ROEBridgeBio Pharma operating marginPenumbra operating marginBridgeBio Pharma revenue growthPenumbra revenue growthBridgeBio Pharma free cash flowPenumbra free cash flow
BridgeBio Pharma & Penumbra appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.